期刊文献+

阿托伐他汀对COPD大鼠转化生长因子β1及胶原表达的干预作用

Intervention of atorvastatin on transforming growth factor-β1 and collagen in COPD rat models
下载PDF
导出
摘要 目的观察慢性阻塞性肺疾病(COPD)大鼠支气管肺组织转化生长因子(TGF)-β1和胶原表达的变化特点以及两者相关的关系,探讨阿托伐他汀对支气管肺组织TGF-β1和胶原表达的干预作用。方法将雄性SD大鼠分成3组(健康对照组、COPD模型组和阿托伐他汀干预组),10周后用小动物肺功能仪测定气道阻力(RL)和动态顺应性(Cdyn);观察各组大鼠支气管肺组织的病理特征;测定支气管肺组织的胶原表达率和TGF-β1含量。比较各组支气管肺组织TGF-β1含量,支气管肺组织中胶原的表达率,以及两者相关性。结果(1)COPD模型组基本符合人类COPD病理生理变化。外周细支气管平滑肌层和细胞外基质胶原较健康对照组大鼠明显增多。阿托伐他汀干预组与COPD模型组比较,RL减少(P<0.01),Cdyn增加(P<0.01)。(2)COPD模型组TGF-β1蛋白(5.66±0.35)μg·L^(-1),较阿托伐他汀干预组(3.25±0.69)μg·L^(-1)升高明显(P<0.01),健康对照组(1.62±0.46)μg·L^(-1),与另两组相比降低明显(均P<0.01)。(3)COPD模型组支气管肺组织胶原表达率为(17.18±5.34)%,较健康对照组[(7.42±2.97)%1增高(P<0.01),阿托伐他汀干预组为(11.94±4.03)%,较健康对照组升高(P<0.05),但较COPD摸型组降低(P<0.01)。(4)各组支气管肺组织TGF-β1含量与胶原表达率呈显著正相关(r=0.802,P<0.01)。结论(1)慢性烟薰和气道内滴入LPS能构建含有气道重构特征的COPD大鼠模型。(2)支气管肺组织胶原沉积增多是COPD气道重构的重要病理变化。胶原表达率与TGF-β1呈正相关,表明TGF-β1在COPD气道重构中起重要作用。(3)早期应用阿托伐他汀可明显抑制气道TGF-β1的表达,影响COPD大鼠气道重构的发生、发展。 Objective To investigate the effect of atorvastatin on the expression of transforming growth factor-β1 (TGF-β1) and col agen in rat model of chronic obstructive pulmonary disease (COPD). Methods Male SD rats were divided in-to three groups; control group, COPD model group and atorvastatin intervention group. After 10 weeks,airway resistance (RL) and dynamic compliance (Cdyn) was measured;the pathological features of lung tissue of three groups were observed;the ex-pressions of TGF-β1 and col agen content in bronchial and lung tissue were measured. Results In COPD model the peripheral bronchiolar smooth muscle layer and collagen in extracel ular matrix increased significantly compared to the healthy control group. In intervention group RL reduced (P〈0.01) and Cdyn increased (P〈0.01) compared to model group. The expressions of TGF-β1 of COPD model group was 5.66±0.35/μg·L-1, which was significantly higher than that in intervention group (3.25± 0.69/μg·L-1, P〈0.01) and healthy control group (1.62±0.46/μg·L-1, P〈0.01). The expression of col agen of bronchial and pul-monary tissue in COPD group was (17.18 ± 5.34)%, which was higher than that in healthy group (7.42±2.97%, P〈0.01), the expression of col agen of intervention group was (11.94 ± 4.03)%, which was higher than that in healthy group(P〈0.05) and low-er than that in COPD group (P〈0.01). The expression of TGF-β1 was positively correlated with collagen expression in bronchial and pulmonary tissue (r=0.802, P〈0.01). Conclusion The increased col agen deposition in bronchial and pulmonary tissue is an important pathological changes of COPD airway remodeling, which is associated with up-regulation of TGF-β1 expression. Early administration of atorvastatin can significantly inhibit TGF-β1 expression and interfere in the development of COPD rat air-way remodeling.
作者 王建岗 刘进
出处 《浙江医学》 CAS 2013年第10期859-862,共4页 Zhejiang Medical Journal
关键词 慢性阻塞性肺疾病 转化生长因子-Β1 胶原阿托伐他汀 Chronic obstructive pulmonary disease Transforming growth factor-β1 Collagen Atorvastatin
  • 相关文献

参考文献15

  • 1Mathers C D, Loncar D. Projections of global mortality and bur-den of disease from 2002 to 2030[J]. PLOS Med, 2006, 3(11);34-42.
  • 2Ind P W.COPD disease progression and airway inflammation:uncoupled by smoking cessation[J]+ Eur Respir J, 2005, 26(5);764-766.
  • 3XIE Qiangmin.ZENG Linghui,ZHENG Yixiong.et al.Bronchodilat-ing effects of bambuterol on bronchocnstriction in guinea pigs[J].Acta Pharmacologica Sinica, 1999,20(7):651 -654.
  • 4Rubio M USanchez-cifuentes M V,Ortegam,et al. N-acetylysteineprevents cigarette smoke in-duced small airways alterations inrats [J].Eur Respir J,2000,15⑶:505-511.
  • 5Bergeron C, Boulet L P. Structural changes in airway diseases:characteristics,mechanisms,consequences and pharmacologicmodulation [J]. Chest,2006,129(4): 1068-1087.
  • 6李红梅,崔德健,马楠,陆连荣,高亚兵,崔学梅,王德文.细胞外基质重塑在大鼠慢性阻塞性肺疾病模型气流阻塞中的作用[J].中华结核和呼吸杂志,2002,25(7):403-407. 被引量:29
  • 7高鸿美,焦光宇,毕涛,李胜岐.脂多糖致大鼠急性肺损伤早期I型前胶原羧基端肽及转化生长因子β_1的表达[J].中华结核和呼吸杂志,2007,30(9):703-704. 被引量:2
  • 8蔡后荣,戴令娟,郑培德,孟凡青.肺纤维化大鼠肺组织转化生长因子β_1和前胶原基因的表达[J].中华医学杂志,2001,81(4):247-248. 被引量:23
  • 9Chua F, Sly P D, Laurent G J. Pediatric lung disease: from pro-teinases to pulmonary fibrosis[J]. Pediatr Pulmonol, 2005, 39(5):392-401.
  • 10Takizawa H, Tanaka M, Takami K, et al. Increased expressionof transforming growth factor- betal in small airway epitheliumform tobacco smokers and patients with chronic obstructivepulmonary disease[J], Am J Pespir Crit Care Med, 2001,163;1476-1483.

二级参考文献28

  • 1董碧蓉,周静,王曾礼.慢性阻塞性肺疾病患者胶原成份改变的临床意义[J].中华结核和呼吸杂志,1995,18(5):301-302. 被引量:6
  • 2Sambrook j Fritsch EF.分子克隆实验指南(第2版)[M].北京:科学出版社,1992..
  • 3王迪浔.病理生理学[M].北京:人民卫生出版社,1996.109-112.
  • 4金冬雁(译),分子克隆实验指南(第2版),1992年,343页
  • 5Raghow R,J Clin Invest,1989年,84卷,1836页
  • 6Crestani B, Cornillet P, Dehoux M,et al. Alveolar type II epithelial cells produce interleukin-6 in vitro and in vivo. Regulation by alveolar macrophage secretory products[J]. J Clin Invest,1994,94(2): 731-740.
  • 7Zhang FL, Casey PJ. Protein prenylation: mechanisms and functional consequences[J]. Annu Rev Biochem,1996,65:241-269.
  • 8Kwak B. Statins as a newly recognized type of immunomodulator[J]. Nat Med,2000,6(12):1399-1402.
  • 9Diomede L,Albani D,Sottocorno M,et al.In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products[J]. Arterioscler Thromb Vasc Biol, 2001,21(8):1327-1332.
  • 10Stalker TJ,Lefer AM,Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid[J]. Br J Pharmacol,2001,133(3): 406-412.

共引文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部